CoagulopathyMANAGEMENT

HEMATOLOGIC AND ONCOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

462 items

☷ Legend

⚲

Cardiovascular Presentations66▾

Respiratory Presentations47▾

Neurological Presentations77▾

Gastrointestinal Presentations63▾

Genitourinary and Reproductive Presentations44▾

Infectious Disease Presentations146▾

Trauma Presentations88▾

Toxicologic Presentations67▾

Psychiatric Presentations25▾

Musculoskeletal and Rheumatologic Presentations89▾

Dermatology Presentations21▾

Environmental and Exposure Presentations26▾

Hematologic and Oncologic Presentations30▾

Acute chest syndrome Acute Hemolytic Transfusion Reaction Aplastic Anemia (Crisis)Autoimmune Hemolytic Anemia Coagulopathy Delayed Hemolytic Transfusion Reaction Disseminated Intravascular Coagulation (DIC)Essential Thrombocythemia Febrile Non-hemolytic Transfusion Reaction Graft Versus Host Disease (Acute)Hemolytic Uremic Syndrome (HUS)Hemophilia A (Bleeding Crisis)Heparin-Induced Thrombocytopenia (HIT)Hyperviscosity syndrome Immune Thrombocytopenic Purpura (ITP)Leukemoid Reaction Myelofibrosis Paroxysmal Nocturnal Hemoglobinuria Polycythemia Vera (Crisis)Pure Red Cell Aplasia Sickle Cell (Acute Chest Syndrome)Sickle Cell (Splenic Sequestration)Sickle cell crisis (vaso-occlusive)Symptomatic anemia Thrombocytopenia (severe)Thrombotic Thrombocytopenic Purpura (TTP)Transfusion-Associated Circulatory Overload (TACO)Transfusion-Related Acute Lung Injury (TRALI)Tumor lysis syndrome Von Willebrand Disease (Bleeding)

Pediatric-Specific Presentations13▾

Endocrine and Metabolic Presentations42▾

ENT and Maxillofacial Presentations21▾

Ophthalmologic Presentations15▾

Obstetric Presentations17▾

Systemic and Miscellaneous Presentations15▾

01Approach to the Critical Patient/attcp53

Immediate priorities

›Stabilization and bleeding control

›If airway compromise or massive hematemesis, initiate RSI with suction-ready setup

›Two large-bore IV or IO

›Warming measures and active rewarming if hypothermia

›If hemorrhagic shock, activate massive transfusion protocol

›Balanced transfusion strategy 1:1:1 RBC:plasma:platelets as initial empiric target

›Permissive hypotension strategy if uncontrolled traumatic hemorrhage and no TBI

›Source control

›Direct pressure and tourniquet for extremity bleeding

›Pelvic binder for suspected pelvic fracture hemorrhage

›Hemodynamic targets and monitoring

›Shock recognition

›Lactate trend for adequacy of resuscitation

›Urine output target 0.5 mL/kg/hour adult

›Monitoring

›Continuous ECG and pulse oximetry

›Arterial line if ongoing vasoactive infusions or refractory shock

›Early high-risk triggers

›Intracranial hemorrhage on anticoagulant

›Immediate reversal pathway activation

›Neurosurgery consultation and repeat imaging plan

›Suspected DIC with active bleeding

›Treat trigger and targeted blood component therapy

›Massive GI bleed with coagulopathy

›Early endoscopy or IR activation based on hemodynamics

Initial diagnostic framing

›Coagulopathy phenotype

›Primary hemostasis defect pattern

›Mucocutaneous bleeding and petechiae

›Immediate bleeding after minor trauma

›Secondary hemostasis defect pattern

›Deep tissue hematomas and hemarthroses

›Delayed bleeding after procedures

›Mixed pattern

›DIC

›Severe liver failure

›Medication and iatrogenic drivers

›Anticoagulants

›Warfarin

›Direct factor Xa inhibitors

›Direct thrombin inhibitor

›Unfractionated heparin and LMWH

›Antiplatelets

›Aspirin

›P2Y12 inhibitors

›Thrombolytics within prior 24 hours

›Alteplase or tenecteplase exposure

Early consults

›Team activation

›Hematology for suspected factor inhibitor, hemophilia, vWD, refractory bleeding

›Access to factor concentrates and specialized assays

›Transfusion medicine and blood bank

›Massive transfusion coordination and special products

›Surgery, IR, GI, OB

›Site-specific hemostasis procedures

02History/hx47

Bleeding characterization

›Bleeding history

›Site pattern

›Epistaxis, gingival bleeding, menorrhagia

›Hematemesis, melena, hematochezia

›Hematuria

›Intramuscular hematoma, compartment symptoms

›Time course

›Sudden onset after trauma or procedure

›Spontaneous onset at rest

›Severity markers

›Syncope or presyncope

›Dyspnea or chest pain suggesting anemia

Risk factors and exposures

›Medication and toxin exposures

›Anticoagulant name and last dose time

›Warfarin with INR target and recent INR

›Apixaban, rivaroxaban, edoxaban last dose time

›Dabigatran last dose time

›Heparin infusion or LMWH timing

›Antiplatelet use

›Aspirin dose and last dose time

›Clopidogrel, prasugrel, ticagrelor last dose time

›Antibiotics and drug interactions

›TMP-SMX, metronidazole, azoles increasing warfarin effect

›Alcohol and poor oral intake

›Vitamin K deficiency risk

›Systemic illness and triggers

›Sepsis or severe infection

›DIC risk

›Liver disease

›Cirrhosis, jaundice, ascites

›Malignancy

›DIC and hyperfibrinolysis risk

›Pregnancy and postpartum

›Placental abruption risk

›Postpartum hemorrhage risk

Personal and family bleeding disorders

›Congenital bleeding disorder clues

›Childhood bleeding episodes

›Prolonged bleeding after dental work

›Hemarthroses

›Family history

›Hemophilia A or B

›von Willebrand disease

›Acquired bleeding disorder clues

›New spontaneous bruising in older adult

›Acquired hemophilia A consideration

›Autoimmune disease or postpartum state

›Factor VIII inhibitor risk

03Physical Exam/exam34

Bleeding and perfusion exam

›Bleeding distribution

›Mucocutaneous findings

›Petechiae

›Purpura

›Gingival bleeding

›Deep bleeding findings

›Large ecchymoses

›Tense compartments and pain out of proportion

›Joint swelling and reduced range of motion

›Perfusion and shock signs

›Hemodynamic instability

›Narrow pulse pressure

›Cool clammy extremities

›End-organ hypoperfusion

›Altered mental status

›Oliguria

Focused site-specific exam

›Neurologic exam

›Intracranial bleeding red flags

›Focal deficit

›Severe headache

›Declining level of consciousness

›Abdominal and pelvic exam

›Intra-abdominal bleeding signs

›Peritonitis

›Abdominal distension

›Skin and soft tissue exam

›Necrosis or livedo

›Purpura fulminans consideration

›Warfarin skin necrosis consideration

PITFALLS

›Pitfalls

›Normal vital signs early in significant blood loss

›Young healthy patients with compensated shock

›Normal INR in factor Xa inhibitor exposure

›INR not reliable for apixaban or rivaroxaban effect

04Differential Diagnosis/ddx35

Life-threatening causes of coagulopathy with bleeding

›High-risk etiologies

›Anticoagulant-associated bleeding

›Warfarin-related coagulopathy

›ICD-10 D68.32

›Direct oral anticoagulant-associated bleeding

›ICD-10 D68.32 and T45.515A adverse effect of anticoagulants

›Disseminated intravascular coagulation

›ICD-10 D65

›Severe hepatic failure with coagulopathy

›ICD-10 K72.90 with D68.4 acquired coagulation factor deficiency

›Massive transfusion dilutional coagulopathy

›ICD-10 D68.9

›Hyperfibrinolysis

›Trauma-associated coagulopathy

Inherited and acquired bleeding disorders

›Secondary hemostasis disorders

›Hemophilia A factor VIII deficiency

›ICD-10 D66

›Hemophilia B factor IX deficiency

›ICD-10 D67

›Acquired hemophilia A factor VIII inhibitor

›ICD-10 D68.311

›Vitamin K deficiency

›ICD-10 E56.1 with D68.4

›Primary hemostasis disorders

›von Willebrand disease

›ICD-10 D68.0

›Platelet dysfunction from uremia

›ICD-10 N18 with D69.9 bleeding disorder

Mimics and alternate explanations

›Non-coagulopathy bleeding causes

›Structural GI lesion

›Peptic ulcer disease

›Variceal hemorrhage

›Gynecologic causes

›Ectopic pregnancy

›Uterine atony postpartum

05Laboratory Tests/lt38

Core bleeding panel

›Baseline coagulation and anemia evaluation

›Complete blood count for anemia and platelet count

›Hemoglobin trend and reticulocyte response

›Platelet count trend and smear review

›PT and INR for extrinsic pathway and vitamin K dependent factors

›Marked INR elevation consistent with warfarin effect or severe hepatic dysfunction

›INR may be minimally changed in factor Xa inhibitor exposure

›aPTT for intrinsic pathway and heparin effect

›Marked aPTT prolongation consistent with UFH or factor VIII inhibitor

›Fibrinogen for consumption and dilution

›Target fibrinogen at least 1.5 to 2.0 g/L in active bleeding

›Type and screen or type and crossmatch

›Massive transfusion preparation

DIC and consumption evaluation

›DIC supportive labs

›D-dimer or fibrin degradation products

›Strongly elevated in DIC and hyperfibrinolysis

›Peripheral smear

›Schistocytes supporting microangiopathy

›Antithrombin level if institutional protocol

›Low level supporting consumption

Drug-specific assays

›Anticoagulant effect testing

›Anti-factor Xa level calibrated for heparin

›UFH or LMWH quantification when available

›Direct factor Xa inhibitor level if available

›Supports reversal decisions in borderline scenarios

›Thrombin time for dabigatran exposure

›Normal thrombin time argues against clinically significant dabigatran effect

Additional labs for contributors

›Contributor assessment

›Creatinine and eGFR for DOAC clearance estimation

›Dabigatran highly renal cleared

›Liver panel for hepatic synthetic dysfunction

›Albumin and bilirubin as severity markers

›Calcium and ionized calcium during massive transfusion

›Citrate toxicity risk with hypocalcemia

Viscoelastic testing

›TEG or ROTEM if available

›Global hemostasis assessment

›Guides fibrinogen, platelet, and plasma therapy

›Identifies hyperfibrinolysis for TXA decision

06Diagnostic Tests/dt35

Scoring Systems

›Clinical scoring tools

›ISTH overt DIC score

›Platelet count points based on degree of thrombocytopenia

›PT prolongation points based on seconds prolonged

›D-dimer or fibrin markers points based on elevation

›Fibrinogen level points based on low level

›ISTH overt DIC score interpretation

›Score at least 5 compatible with overt DIC in appropriate clinical setting

›Serial scoring for trend and response

›4T score for heparin-induced thrombocytopenia when heparin exposure

›Thrombocytopenia magnitude

›Timing relative to heparin exposure

›Thrombosis or other sequelae

›Other causes of thrombocytopenia

MRI

›MRI indications

›Suspected spinal epidural hematoma

›Back pain with neurologic deficit on anticoagulant

›Suspected hemarthrosis with occult fracture or soft tissue bleed delineation

›Persistent joint pain and swelling with unclear diagnosis

›Contraindications and limitations

›Unstable patients requiring immediate CT or operative control

›CT for occult or internal bleeding

›Noncontrast CT head for anticoagulant-associated head trauma or neurologic deficit

›Repeat CT based on symptoms, anticoagulant status, and initial findings

›CT abdomen and pelvis with contrast for suspected retroperitoneal bleed

›Flank pain, femoral neuropathy, hypotension on anticoagulant

›CT angiography for active arterial bleeding localization

›Consider IR embolization planning

Ultrasound

›Ultrasound applications

›POCUS FAST for hemoperitoneum in trauma or unstable patient

›Pericardial effusion assessment for tamponade

›Soft tissue ultrasound for expanding hematoma

›Pseudoaneurysm consideration after arterial puncture

›Obstetric ultrasound in pregnancy with bleeding

›Placental location and abruption evaluation adjunct

07Disposition/dispo18

Level of care

›Admission and monitoring criteria

›ICU criteria

›Ongoing transfusion requirement

›Hemodynamic instability or vasopressor need

›Intracranial hemorrhage or critical site bleeding

›Step-down or ward criteria

›Stable after reversal and no ongoing bleeding

›Need for serial labs and observation

Transfer criteria

›Transfer to higher level care

›Need for neurosurgery, IR, or factor concentrate not available

›Hemophilia with major bleed and no factor supply

›Suspected acquired hemophilia needing bypassing agent access

Discharge criteria

›Discharge considerations

›Minor bleeding resolved and stable hemoglobin

›Clear medication plan and follow-up arranged

›Return precautions for recurrent bleeding

›Reliable access to repeat INR or anticoagulation clinic if warfarin adjustments

›Same-week lab plan

08Treatment/t114

General hemostatic strategy

›Treatment framework

›Local control and procedural hemostasis

›Topical tranexamic acid for epistaxis

›Nasal packing or cautery as indicated

›Blood component therapy guided by labs and bleeding severity

›RBC transfusion for symptomatic anemia or shock

›Plasma, fibrinogen, platelets based on deficits

›Anticoagulant reversal based on agent and bleeding site

›Critical site bleeding includes intracranial, intraspinal, pericardial, retroperitoneal

Warfarin reversal

›Warfarin-associated major bleeding

›Four-factor prothrombin complex concentrate

›Dose based on INR and body weight per institutional protocol

›Common dosing framework 25 to 50 units/kg with maximum per product label

›Repeat INR 30 to 60 minutes after infusion completion

›Class I recommendation in many society guidelines for life-threatening VKA bleeding

›Faster INR correction compared with plasma

›Vitamin K

›10 mg IV slow infusion for major bleeding

›Onset 4 to 6 hours with sustained effect

›Repeat dosing based on INR trend

›Plasma if PCC unavailable

›15 mL/kg as initial dose

›Volume overload risk and slower correction

Direct oral anticoagulant reversal

›Factor Xa inhibitor major bleeding

›Andexanet alfa when available and criteria met

›Dosing based on agent, last dose, and time since last dose per product protocol

›Bolus followed by 2-hour infusion

›Thrombotic event risk and need for restart planning

›Class IIa recommendation in some guidelines for life-threatening bleeding

›Four-factor PCC when andexanet unavailable or not indicated

›50 units/kg IV once commonly used in practice

›Consider repeat based on clinical course and labs

›Thrombosis risk counseling and monitoring

›Dabigatran major bleeding

›Idarucizumab

›5 g IV as two consecutive 2.5 g doses

›Rapid neutralization of dabigatran effect

›Consider repeat dose in rebound with renal failure and ongoing bleeding

›Hemodialysis consideration

›Severe renal failure with persistent dabigatran effect

Heparin and LMWH reversal

›Unfractionated heparin bleeding

›Protamine sulfate

›Dose based on heparin units received in prior 2 to 3 hours

›Maximum single dose commonly 50 mg

›Infuse slowly to reduce hypotension and anaphylactoid reactions

›LMWH bleeding

›Protamine partial reversal

›Dose based on LMWH timing and dose

›Incomplete anti-Xa reversal

›Consider repeat protamine if ongoing bleeding and recent LMWH dose

Antiplatelet-associated bleeding

›Antiplatelet therapy with major bleeding

›Platelet transfusion in selected scenarios

›Life-threatening bleeding with recent P2Y12 inhibitor and planned emergent surgery

›Limited evidence and potential harm in spontaneous ICH contexts

›Desmopressin for platelet dysfunction

›0.3 mcg/kg IV over 15 to 30 minutes

›Hyponatremia and fluid restriction monitoring

›Consider in uremic platelet dysfunction and antiplatelet-associated ICH per local guideline

Fibrinogen replacement

›Hypofibrinogenemia with active bleeding

›Cryoprecipitate

›Initial adult dose commonly 10 units

›Recheck fibrinogen after administration

›Target at least 1.5 to 2.0 g/L in major bleeding

›Fibrinogen concentrate if available

›Dose based on desired increment and body weight

›Faster delivery and lower volume than cryoprecipitate

Plasma replacement

›Plasma indications in bleeding

›Multiple factor deficiency with bleeding and prolonged PT or aPTT

›DIC with bleeding and prolonged PT

›Liver failure with bleeding and procedural needs

›Dosing

›15 to 20 mL/kg initial dose

›Reassess coag tests and clinical bleeding

Platelet thresholds in bleeding

›Platelet transfusion targets

›Major active bleeding

›Target at least 50 x10^9/L

›Intracranial hemorrhage or neurosurgery

›Target at least 100 x10^9/L

›Massive transfusion

›Empiric platelets per MTP with adjustment by counts or TEG

DIC management

›DIC with bleeding strategy

›Trigger treatment

›Early sepsis management bundle

›Obstetric source control if placental abruption or retained products

›Component therapy guided by bleeding and labs

›Platelets to target at least 50 x10^9/L in bleeding

›Fibrinogen replacement to target at least 1.5 g/L

›Plasma for prolonged PT with active bleeding

›Anticoagulation considerations

›If predominant thrombosis and no active bleeding, individualized heparin strategy with hematology

Tranexamic acid

›TXA use in selected bleeding states

›Trauma within 3 hours of injury

›1 g IV over 10 minutes then 1 g IV over 8 hours

›Mortality benefit demonstrated in large pragmatic trials

›Postpartum hemorrhage

›1 g IV over 10 minutes

›Second 1 g dose if bleeding continues after 30 minutes or recurs within 24 hours

›Contraindications and cautions

›Active intravascular clotting with high thrombotic risk

›Dose adjustment in severe renal impairment

Acquired hemophilia and factor inhibitor emergencies

›Suspected acquired hemophilia A with major bleeding

›Mixing study pattern

›Failure to correct aPTT with mix suggests inhibitor

›Hemostatic agents

›Recombinant activated factor VII 90 mcg/kg IV every 2 to 3 hours until hemostasis

›Activated prothrombin complex concentrate 50 to 100 units/kg IV every 8 to 12 hours

›Immunosuppression initiation with hematology

›Steroids with or without cyclophosphamide or rituximab

Procedure planning in coagulopathy

›Procedural bleeding mitigation

›Central line selection

›Ultrasound-guided compressible site preferred

›Pre-procedure targets individualized by bleeding risk

›Platelets and fibrinogen optimization for high-risk procedures

›Avoid routine correction of mildly elevated INR in stable cirrhosis without bleeding

09Special Populations/sp24

Pregnancy

›Pregnancy-related considerations

›Physiologic coagulation changes

›Higher fibrinogen baseline with pregnancy

›Increased thrombotic risk with reversal agents

›Postpartum hemorrhage coagulopathy

›Early TXA within 3 hours of onset

›Fibrinogen replacement early if low or falling rapidly

›Anticoagulant use

›LMWH common with partial protamine reversibility

›Warfarin generally avoided but possible postpartum

Geriatric

›Older adult considerations

›Higher anticoagulant exposure prevalence

›Polypharmacy and interaction risk

›Increased intracranial bleed risk

›Lower threshold for CT head after falls

›Renal impairment affecting DOAC clearance

›Dabigatran and factor Xa inhibitor accumulation risk

Pediatrics

›Pediatric considerations

›Weight-based dosing for reversal agents and blood components

›PCC, protamine, TXA dosing per kg

›Congenital bleeding disorders more common relative to adults

›Hemophilia and vWD evaluation pathway

›Child protection considerations

›Bruising pattern inconsistent with history requires safeguarding workflow

10Background/b36

Epidemiology

›Population patterns

›Anticoagulant-associated bleeding increasing with aging populations

›DOAC use prevalent in atrial fibrillation and VTE

›Inherited bleeding disorders prevalence

›Hemophilia A rare and X-linked

›von Willebrand disease most common inherited bleeding disorder

Pathophysiology

›Hemostasis overview

›Primary hemostasis

›Platelet adhesion and aggregation

›von Willebrand factor role in platelet adhesion

›Secondary hemostasis

›Coagulation cascade generating thrombin and fibrin

›Vitamin K dependent factors II, VII, IX, X

›Fibrinolysis

›Plasmin-mediated clot breakdown

›Hyperfibrinolysis contributing to traumatic coagulopathy

›Common acquired coagulopathy mechanisms

›DIC

›Widespread thrombin generation with consumption of platelets and factors

›Secondary fibrinolysis with elevated D-dimer

›Liver disease

›Reduced synthesis of procoagulant and anticoagulant proteins

›Rebalanced hemostasis with bleeding and thrombosis risk

Therapeutic Considerations

›Reversal principles

›Match reversal to agent and bleeding severity

›Critical site bleeding requires immediate reversal regardless of lab appearance

›Thrombosis risk after reversal

›Plan for anticoagulant restart timing with specialty input

›Goal-directed transfusion

›Use fibrinogen and platelet targets to avoid overtransfusion

›Viscoelastic testing improves targeting where available

›Evidence and guideline framing

›Class I principle

›Immediate reversal for life-threatening anticoagulant-associated bleeding supported by consensus and observational outcomes

›Class IIa principle

›Specific antidotes preferred when available for qualifying DOAC bleeds

11Patient Discharge Instructions/pdi17

Copy discharge instructions

›Discharge instructions for resolved minor bleeding with coagulopathy risk

›Medication plan

›Clear instructions on holding or restarting anticoagulant

›Avoid NSAIDs unless specifically advised

›Follow-up

›INR check date and location if on warfarin

›Anticoagulation clinic or prescriber follow-up within 1 to 3 days if dose changed

›Return to ED immediately

›Any head injury or new headache while on anticoagulant

›Vomiting blood or black tarry stools

›Large-volume rectal bleeding

›Shortness of breath, chest pain, fainting, or severe weakness

›Rapidly enlarging bruising or swelling

›New neurologic symptoms

›Activity guidance

›Avoid contact sports and high-fall-risk activities until cleared

›Use soft toothbrush and avoid aggressive flossing if mucosal bleeding tendency

12References/r11

Clinical guidelines and evidence sources

›Key references

›Anticoagulant reversal society guidelines including ACC, AHA, ISTH, and hematology consensus statements

›Warfarin major bleeding reversal recommendations including PCC plus IV vitamin K

›DOAC major bleeding reversal recommendations including specific antidotes when available

›ISTH guidance on DIC diagnosis and ISTH overt DIC scoring system

›Serial scoring for monitoring progression and response

›Trauma hemorrhage evidence for TXA timing within 3 hours

›Standard dosing 1 g then 1 g infusion regimen

›Obstetric hemorrhage evidence for TXA use

›Early administration and repeat dosing criteria

›Source file

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed June 16, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.